Teva Pharmaceutical Industries Limited (TLV:TEVA)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 110.10B +70.0% |
| Revenue (ttm) | 54.78B +4.4% |
| Net Income | 4.94B |
| EPS | 4.23 |
| Shares Out | n/a |
| PE Ratio | 22.28 |
| Forward PE | 14.75 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 413,893 |
| Open | 9,501.00 |
| Previous Close | 9,530.00 |
| Day's Range | 9,484.00 - 9,670.00 |
| 52-Week Range | 5,305.00 - 11,350.00 |
| Beta | 0.86 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 29, 2026 |
About TLV:TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
News
Colin Cieszynski's Past Picks: First Quantum Minerals, Teva Pharmaceuticals & BMO Global Gold Index
Colin Cieszynski, portfolio manager & chief market strategist at SIA Wealth Management, discusses his past stock picks and how they're doing in the market today
Teva (TEVA) Lawsuit Against Eli Lilly Revived by Appeals Court
Teva (TEVA) Lawsuit Against Eli Lilly Revived by Appeals Court
US appeals court revives Teva lawsuit over Lilly osteoporosis drug
A U.S. appeals court on Monday revived a lawsuit brought by generic drugmaker Teva Pharmaceuticals that accuses Eli Lilly of breaching a settlement agreement that allowed Teva to market a generic vers...
Teva Pharmaceutical Industries' Anti-IL-15 Antibody Shows Promise in Vitiligo Study
Teva Pharmaceutical Industries NYSE: TEVA said its internally developed anti-IL-15 antibody produced encouraging 24-week efficacy results in a phase 1b proof-of-concept study for vitiligo, as the comp...
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
Novartis AG maintains a highly profitable portfolio of innovative medicines with significant net margins. Teva Pharmaceutical Industries is executing a turnaround focused on biosimilars and high-growt...
Teva (TEVA) Secures Global Licensing Deal for Biosimilar Ocrevus
Teva (TEVA) Secures Global Licensing Deal for Biosimilar Ocrevus
Teva And Polpharma Enter Licensing Agreement For Ocrevus Biosimilar Candidate In Multiple Sclerosis
(RTTNews) - Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (TEVA), and Polpharma Biologics International AG announced on Thursday that they have entered in...
Teva (TEVA) Expands Biosimilar Portfolio in Canada with New Agreement
Teva (TEVA) Expands Biosimilar Portfolio in Canada with New Agreement
Teva And Samsung Bioepis Enter Commercialization Agreement For OPUVIZ In Canada
(RTTNews) - On Thursday, Teva Pharmaceutical Industries Ltd. (TEVA) and Samsung Bioepis Co., Ltd., a unit of Samsung Epis Holdings Co. Ltd. (0126Z0.KS), announced that they have entered into a license...
Teva, Polpharma enter global licensing agreement for Ocrevus biosimilar
Teva (TEVA) Pharmaceuticals and Polpharma Biologics International announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ propo...
Teva And Polpharma Biologics Ink Global Licensing Deal For Ocrevus Biosimilar
(RTTNews) - Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (TEVA) and Polpharma Biologics International AG announced Thursday a global licensing agreement ...
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
TEL AVIV, Israel & ZUG, Switzerland--(BUSINESS WIRE)--Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics Interna...
Teva, Polpharma Biologics announce global licensing agreement
Teva (TEVA) Pharmaceuticals International, a subsidiary of Teva, and Polpharma Biologics announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Pol...
Teva, Samsung Bioepis enter commercialization agreement for OPUVIZ
Teva (TEVA) Pharmaceutical Industries and Samsung Bioepis announced that the companies have entered into a license and commercialization agreement for OPUVIZ, a biosimilar referencing Eylea, in Canada...
A Look at Teva Pharmaceutical Industries Ltd (TEVA) After 4.1% Decline -- GF Value $20. ...
A Look at Teva Pharmaceutical Industries Ltd (TEVA) After 4.1% Decline -- GF Value $20.26 vs Price $33.24
Teva (TEVA) Advances Vitiligo Treatment into Phase 2b Study
Teva (TEVA) Advances Vitiligo Treatment into Phase 2b Study
Teva Pharmaceutical Industries Transcript: Study result
A phase I-B study of anti-IL-15 in vitiligo showed 42% of patients achieved ≥50% facial improvement and 21% achieved ≥75% at 24 weeks, with high patient satisfaction and favorable safety. The antibody's quarterly dosing and efficacy compare well to oral JAKs, and broader development in related diseases is underway.
Teva Pharmaceutical Industries Press release: Study result
Teva Pharmaceutical Industries issued a press release on July 7, 2026, disclosing material business information to investors.
Teva Pharmaceutical Industries Slides: Study result
Teva Pharmaceutical Industries has posted slides in relation to its latest quarterly earnings report, which was published on July 7, 2026.
Teva to advance TEV-‘408 into Phase 2b study in vitiligo in Q4
Teva (TEVA) announced plans to advance its TEV-‘408, an investigational anti-interleukin-15 monoclonal antibody, into a Phase 2b study in vitiligo in the fourth quarter of 2026. The decision follows e...
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
Eli Lilly and dominance in weight loss and diabetes treatments continues to fuel massive revenue growth. Teva Pharmaceutical Industries offers a value-oriented play as it moves past legal hurdles and ...
Is Teva Pharmaceutical Industries Ltd (TEVA) Overvalued After 3.6% Rally? GF Value Says Overvalued
Is Teva Pharmaceutical Industries Ltd (TEVA) Overvalued After 3.6% Rally? GF Value Says Overvalued
SPDW, SPOT, TEVA, SE: ETF Inflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Portfolio Developed World ex-US ETF (Symbol: SPDW) where we have ...
Teva Pharmaceutical Industries Ltd (TEVA) Stock Up 3. ...
Teva Pharmaceutical Industries Ltd (TEVA) Stock Up 3.1% but GF Value Says Overvalued -- GF Score: 54/100
Insider Sell: Matthew Shields Sells 9,989 Shares of Teva Pharmaceutical Industries Ltd (TEVA)
Insider Sell: Matthew Shields Sells 9,989 Shares of Teva Pharmaceutical Industries Ltd (TEVA)